Accession Number : AD1020595


Title :   Enhancing the Immunogenicity of a Tetravalent Dengue DNA Vaccine


Descriptive Note : Technical Report,15 Jul 2015,14 Jul 2016


Corporate Author : Henry M. Jackson Foundation For the Advance of Military Rockville United States


Personal Author(s) : Williams,Maya


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1020595.pdf


Report Date : 01 Aug 2016


Pagination or Media Count : 14


Abstract : Dengue fever ranks among the top infectious diseases that afflict US Military personnel deployed overseas. Developing a successful vaccine to prevent dengue fever in DoD personnel is priority research area for the US DoD. Phase 1 clinical trials demonstrated that the Naval Medical Research Centers DNA based dengue vaccine is safe and well tolerated, but does not elicit a sufficient immune response. The objectives of this project are to conduct studies in non-human primates to enhance the immunogenicity of the vaccine by (a) testing different modes of delivery of dengue DNA vaccine for optimal humoral and T cell responses, and (b) testing the optimal delivery method in conjunction with other vaccine platforms using a heterologous prime-boost regimen. All necessary contracts are in place, the vaccine product is ready and the first vaccinations to address objective (a) are scheduled for early October 2016.


Descriptors :   vaccines , dengue , military personnel , infectious diseases , ANIMAL EXPERIMENTATION


Distribution Statement : APPROVED FOR PUBLIC RELEASE